Immucell
ICCC
Immucell (ICCC) earnings history
Most recent quarter
- Fiscal period
- Q4 2021
- Period end
- Dec 31, 2021
- EPS actual
- −$0.01
- EPS estimate
- −$0.01
- EPS surprise
- +0.00%
- Revenue surprise
- +0.00%
- Revenue
- $5.4M
- Revenue estimate
- $5.4M
- Reported
- Feb 22, 2022
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q4 2021 | Feb 22, 2022 | −$0.01 | −$0.01 | +0.00% | $5.4M | — |
| Q3 2021 | Nov 15, 2021 | −$0.06 | $0.02 | +133.33% | $5.2M | — |
| Q2 2021 | Aug 12, 2021 | −$0.08 | $0.02 | +125.00% | $4.5M | — |
| Q1 2021 | May 13, 2021 | $0.05 | −$0.06 | −220.00% | $4.1M | — |
| Q4 2020 | Feb 23, 2021 | −$0.04 | $0.03 | +175.00% | $3.7M | — |
| Q3 2020 | Nov 12, 2020 | −$0.08 | −$0.04 | +50.00% | $0.00 | — |
| Q2 2020 | Aug 12, 2020 | −$0.10 | −$0.11 | −10.00% | $3.0M | — |
| Q1 2020 | May 13, 2020 | $0.00 | −$0.02 | +0.00% | $4.9M | — |
Quarterly revenue
Frequently asked questions
When did Immucell (ICCC) last report earnings?
Immucell last reported on Feb 22, 2022, covering fiscal Q4 2021.
Did ICCC beat earnings estimates?
Immucell reported EPS of −$0.01 for Q4 2021, in line with the −$0.01 consensus estimate.
How much revenue did ICCC report last quarter?
Immucell reported $5.4M in revenue for Q4 2021, against a consensus estimate of $5.4M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.